A new sequential neoadjuvant therapy strategy for gastric cancer patients with pyloric obstruction
This study demonstrates that a new sequential treatment strategy involving stomach-partitioning gastrojejunostomy (SPGJ) followed by neoadjuvant therapy and radical gastrectomy is a safe and effective approach for gastric cancer patients with pyloric obstruction, enabling oral intake during treatment and achieving high rates of R0 resection and pathological response.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Gastric cancer, a disease that begins in the lining of the stomach, remains one of the most common and deadly cancers worldwide. For many patients, the tumor grows in the lower part of the stomach, near the exit that leads to the small intestine. When the cancer becomes advanced, it can block this exit, a condition known as pyloric obstruction. This blockage prevents food from passing through, leaving patients unable to eat and rapidly becoming malnourished. In standard medical practice, doctors often treat advanced cancer with a combination of chemotherapy and surgery. However, this approach usually requires the patient to be strong enough to swallow and digest food, as the drugs are taken orally and the body needs nutrition to handle the treatment. For patients with a blocked stomach exit, this creates a difficult catch-22: they are too weak to receive the life-saving drugs that could shrink the tumor, but they cannot eat enough to get strong enough to receive them.
A team of researchers from Sichuan Cancer Hospital and other institutions in China has explored a new way to break this cycle. They focused on a small group of seven patients who had advanced stomach cancer causing a complete blockage at the pylorus. Instead of trying to feed these patients through a tube or skipping the pre-surgery treatment entirely, the doctors devised a two-step surgical and medical plan. First, they performed a specialized bypass operation called a stomach-partitioning gastrojejunostomy. In this procedure, the surgeons cut the upper part of the stomach to separate the food path from the tumor. They then connected the healthy upper section of the stomach directly to the small intestine, creating a new route for food to travel. This bypassed the blockage entirely, allowing the patients to eat solid food again. Once the patients could eat and their bodies began to recover, the team administered the standard chemotherapy drugs. After the drugs had done their work to shrink the cancer, the patients underwent a final surgery to remove the tumor and the remaining part of the stomach.
The results of this approach were promising for this small group. All seven patients successfully completed the bypass surgery without major complications. Because the new connection allowed food to pass freely, every patient was able to take in nutrition orally and tolerated the full course of chemotherapy. None of the patients experienced the common problems of food getting stuck or bleeding from the tumor during the treatment phase. When the final surgery was performed, the surgeons were able to remove all visible signs of the cancer in every single case. In two of the seven patients, the chemotherapy was so effective that no cancer cells could be found in the removed tissue at all. The study suggests that this sequential strategy—fixing the eating problem first, then treating the cancer, and finally removing the tumor—can make advanced gastric cancer with obstruction treatable.
However, the researchers are careful to note that this is an early finding based on a very small number of patients. The study was a review of past cases rather than a large-scale test against other methods, and the team did not have long-term data on how these patients fared years later. While the immediate results show that the method is safe and allows for effective drug treatment, the authors state that more research is needed to confirm if this approach leads to better long-term survival rates compared to other treatments. For now, this work offers a new possibility for a group of patients who previously had very few options, turning a situation where they could not eat into one where they could receive the full power of modern cancer therapy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.